Support from Vinnova
More support for Alertix’ acclaimed research. This time from Sweden’s Innovation Agency Vinnova.
Alertix plans to broaden and deepen its clinical documentation to verify initial results from smaller studies. Alertix now receives 300.000 SEK from Sweden's Innovation Agency Vinnova (programme Innovative Startups 1) to conduct a clinical verification study of its veterinary diagnostic biomarker for tumor diseases in dogs.
Alertix has received the innovation award Skapa in Kalmar county and will participate as finalist in the national Skapa award ceremony in Stockholm on the 14th of November.